Darunavir / cobicistat

Oxcarbazepine

Not recommended association.

No pharmaceutical opinion available for this interaction.

Mechanism

Oxcarbazepine can induce the metabolism (CYP 3A4) and decrease the plasma concentration of Darunavir / cobicistat.

Darunavir / cobicistat

Pharmacodynamic effects

Possible decrease of clinical efficacy.

Risk of a possible development of resistance to antiretroviral class.

Recommendations

Monitor for signs and symptoms of therapeutic failure.

Alternative solution(s)

Oxcarbazepine

Pharmacodynamic effects

Recommendations

Avoid association. Choose an alternative.

Alternative solution(s)

Gabapentin, pregabalin, leviracetam.

Monitor

Tests

Darunavir plasma level

CD4+

Viral load HIV

Pharmacokinetic parameters

Comment

Reference
  • 3071
    Darunavir/cobicistat (Prezcobix), Janssen, Ontario, Canada, 7 avril 2017.
  • 3141
    Oxcarbazepine (Trileptal), Novartis, Québec, Canada, 18 mars 2015.
  • 3437
    Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza), Janssen Inc, Ontario, Canada, 3 octobre 2018.